Sagimet Biosciences plans $47.12M equity offering
Sagimet Biosciences plans to sell Series A common stock and pre-funded warrants totaling $47.12M. The capital raise will be co-led by Leerink Partners, TD Securities, and Guggenheim Securities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed